Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models

Article

关键词: APOLIPOPROTEIN-A-I;    HIGH-DENSITY-LIPOPROTEIN;    REVERSE CHOLESTEROL TRANSPORT;    ADENOVIRUS-MEDIATED TRANSFER;    CORONARY-ARTERY DISEASE;    E-DEFICIENT MICE;    TRANSGENIC MICE;    PLASMA-LEVELS;    EXPRESSION;    SUBCLASSES;   

DOI  :  10.1161/01.CIR.99.1.105

来源: SCIE

【 摘 要 】

Background-Apolipoprotein (apo) A-I is the major component of HDL, and it displays antiatherogenic properties. Methods ann Results-The human apoA-I gene has been transferred into different mouse models by use of a recombinant adenovirus under the control of an RSV-LTR promoter (AV RSV apoA-I). Administration of AV RSV apoA-I to C57BL/6 mice resulted in moderate expression of human apoA-I for 3 weeks, leading to a transient elevation (40% at day 11 after injection) of HDL cholesterol concentration. In contrast, administration of AV RSV apoA-I to human apnA-I-transgenic mice induced a large increase of human apoA-I and HDL cholesterol concentrations (300% and 360%, respectively, at day 14 after injection) for 10 weeks, indicating that an immune response to the transgene was one major hurdle for long-term duration of expression. Recombinant adenavirus expressing human apolipoprotein A-I (AV RSV apoA-I) was also injected into human apoA-I-transgenic/apoE-deficient mice, which are prone to develop atherosclerosis. Over a 6-week period, overexpression of human apoA-I inhibited fatty streak lesion formation by 56% in comparison with control. Conclusions-Somatic gene transfer of human apoA-I prevents the development of atherosclerosis in the mouse model.

【 授权许可】

Free